Human Chorionic Gonadotropin (hCG)
Also known as: hCG, HCG, β-hCG, beta-hCG, Chorionic Gonadotropin, hyperglycosylated hCG, hCG-H, hCGβ, free beta-subunit hCG, β-core fragment hCG, bcf-hCG, urinary hCG, u-hCG, recombinant hCG, r-hCG, Ovidrel, Pregnyl
Glycoprotein hormone / Gonadotropin
What it is
Human Chorionic Gonadotropin (hCG) is a hormone used in fertility treatment to trigger ovulation and support early pregnancy. It works by mimicking LH, the hormone that tells the ovaries to release an egg and maintain progesterone levels. Approved for fertility use in many countries; banned by WADA in male athletes.
The scientific side
hCG is a heterodimeric glycoprotein hormone composed of an α-subunit (shared with LH, FSH, TSH) and a unique β-subunit, encoded by the CGB gene cluster. It exists in at least five common molecular forms including regular hCG, sulfated hCG, hyperglycosylated hCG (hCG-H), free hCGβ, and hyperglycosylated free hCGβ. Regular hCG, produced by differentiated syncytiotrophoblast cells, acts as an agonist at the LH/hCG receptor (LHCGR), stimulating progesterone production by corpus luteum cells, maintaining uterine spiral arteries and myometrial quiescence, and supporting early pregnancy (PMID 25707740, PMID 29509368, PMID 19817556). hCG-H, produced by undifferentiated cytotrophoblast cells, is the predominant isoform in the first 2–3 weeks of pregnancy (comprising up to 90% of total hCG) and promotes trophoblast invasion; it activates LHCGR with lower potency than regular hCG and has been reported to act via TGF-β receptor 2 rather than exclusively via LHCGR, though this TGFβR activation has been questioned when highly purified hCG preparations are used. hCG has immunomodulatory properties including modulation of uterine NK cells, Treg cells, and B cells to promote maternal immune tolerance. hCG also stimulates angiogenesis and vasculogenesis via LHCGR expressed on uterine spiral artery mural cells and by inducing VEGF secretion. The free hCGβ subunit and hyperglycosylated free hCGβ function as autocrine growth factors promoting invasion and malignancy in trophoblastic and non-trophoblastic cancers (PMID 22455390, PMID 20654692).
Class: Glycoprotein hormone / Gonadotropin
Administration & storage
- Administration
- Intrauterine (intracavity) administration via embryo transfer catheter — used in RCTs of IC-hCG for subfertile women (PMID: 30341915)Intrauterine injection in mouse uterus — ex vivo experimental model (PMID: 40869294)Standard injectable administration for ovulation triggering in IVF (route not further specified in abstracts) (PMID: 41239008)Standard injectable administration in bovine/porcine animal studies (route not further specified) (PMID: 40273828PMID: 26130853)
- Storage
- No abstracts in the reviewed literature explicitly describe storage conditions for therapeutic hCG preparations. Commercial preparations mentioned include urinary hCG (Pregnyl) and recombinant hCG (Ovitrelle/Ovidrel) (PMID: 30287399, PMID: 41239008), but storage conditions are not stated.
- Cautions
- Ovarian hyperstimulation syndrome (OHSS) is a known risk associated with hCG trigger use in IVF; dual hCG/GnRH agonist trigger protocols were developed in part to reduce OHSS risk.,Commercial hCG preparations (urinary-derived) have been found to contain significant amounts of contaminating growth factors including EGF and TGF-β1, which may cause spurious biological effects in research settings and potentially in clinical preparations; highly purified hCG preparations are recommended for biological studies.,Dose-dependent follicular cyst development was observed in gilts receiving supplemental hCG after standard eCG/hCG treatment; higher doses (200 IU additional) increased cyst frequency significantly.,Elevated hCG levels can be caused by assay interference (heterophilic antibodies, rheumatoid factor, biotin, passive transfer from plasma products) leading to false-positive results and potentially harmful clinical decisions; careful investigation of the source of elevation is essential before initiating treatment (PMID: 39661999, PMID: 31010310, PMID: 29588177).,Sterile technique is required for all injectable and intrauterine administrations to prevent infection.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. Note: PMID 19817556 states that the US FDA considers only regular (intact heterodimeric) hCG as part of a pregnancy test for regulatory purposes, but…
PMID 24275190 states that hCG is determined for doping control in males, but the specific WADA prohibited list status is not explicitly stated in the reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Ovulation induction and triggering in assisted reproduction (IVF/ICSI) Human RCT
- Retrospective cohort of 2641 IVF/ICSI cycles: 2,000 IU hCG in a dual hCG/GnRH agonist trigger yielded more mature oocytes, fertilized embryos, and blastocysts than hCG-only; implantation rate 50.0% vs 32.0% (hCG-only); ongoing pregnancy rates similar (46.8% vs 39.5%); OHSS rates low across all groups. PMID 41239008 Oliva et al., J Assist Reprod Genet 2026
- Review confirms injection of hCG is widely used to induce ovulation in assisted reproduction treatment (ART). PMID 16877746 Stenman et al., Hum Reprod Update 2006
- Intrauterine (intracavity) hCG administration to improve embryo implantation in subfertile women undergoing assisted reproduction Human RCT
- Meta-analysis of 17 RCTs (n=4751): IC-hCG ≥500 IU at cleavage-stage ET improved live birth rate (RR 1.57, 95% CI 1.32–1.87; moderate-quality evidence) and clinical pregnancy rate (RR 1.49, 95% CI 1.32–1.68). No benefit demonstrated for blastocyst-stage ET. No evidence of reduction in miscarriage. PMID 30341915 Craciunas et al., Cochrane Database Syst Rev 2018
- Prevention of recurrent miscarriage (hCG supplementation) Mixed
- Meta-analysis/systematic review: Cochrane database indicated hCG supplementation may prevent further miscarriages (OR 0.26, 95% CI 0.14–0.52); however, trials were not matched for prognostic factors and used urinary (not recombinant) hCG. Authors conclude use remains empiric pending a properly controlled trial. PMID 20653339 Carp, Gynecol Endocrinol 2010
- Corpus luteum support and pregnancy rate improvement in bovine embryo transfer (animal model) Animal studies only
- In beef cows, hCG ≥1000 IU improved luteal area, P4 levels, and pregnancy per embryo transfer (P/ET) vs control. Combining hCG with twice-administered eCG reduced blood perfusion without further improving P/ET. PMID 40273828 Mattos et al., Anim Reprod Sci 2025
- In prepuberal gilts, supplemental hCG (100–200 IU) increased corpora lutea numbers but also increased follicular cysts in a dose-dependent manner, without significantly improving ovulation rates. PMID 26130853 Manjarín et al., Can J Vet Res 2015
- Pregnancy detection and monitoring (serum and urine hCG measurement) Human observational
- Review: hCG tests used for pregnancy detection, early pregnancy detection, prediction of ectopic and spontaneously aborting pregnancies, and prenatal trisomy screening. Most automated tests focus on regular hCG and may miss hCG-H predominant in early pregnancy. PMID 19817556 Cole, Expert Rev Mol Diagn 2009
- Review: pregnancy tests for hCG are used widely in hospital and home settings; also used in prenatal screening and oncology. Future assays require clear nomenclature, defined antibody epitope specificities, and calibration using international reference reagents. PMID 25246381 Berger & Sturgeon, Trends Endocrinol Metab 2014
- Monitoring and prediction of pregnancy outcome after IVF embryo transfer (serum β-hCG cutoff values) Human observational
- Retrospective study: β-hCG cutoff values on day 14 post-cleavage embryo transfer were 89.6 mIU/L (pregnancy vs none), 241.1 mIU/L (biochemical vs clinical pregnancy), 585.9 mIU/L (adverse outcome), and 981.1 mIU/L (singleton vs twin live birth). Higher β-hCG strongly associated with full-term live birth. PMID 35733148 Zhang et al., Reprod Health 2022
- Retrospective study of single blastocyst transfer: β-hCG cutoff values on day 14 for positive outcomes were 194.1, 503.0, 1048.0, and 2590.5 mIU/L. Higher β-hCG groups had significantly lower biochemical pregnancy rates and adverse outcome rates. PMID 36279733 Zhang et al., Reprod Biol 2022
- Retrospective analysis of 1762 IVF cycles: hCG cut-off values of 290 IU/L on day 14 and 2970 IU/L on day 21 post-ET predicted viable pregnancy; 630 and 12,000 IU/L predicted multiple pregnancy. HCG(21)/HCG(14) ratio >15 predicted viable pregnancy. PMID 20207583 Chi et al., Reprod Biomed Online 2010
- Diagnosis and monitoring of gestational trophoblastic disease (GTD) and gestational trophoblastic neoplasia (GTN) Human observational
- Retrospective study of 176 molar pregnancies: hCG ≥1400 IU/L at week 2 post-evacuation (AUC 0.92, aOR 6.51) and hCG ratio at week 2 / post-evacuation ≥0.02 (AUC 0.88, aOR 12.27) independently predicted postmolar GTN. PMID 36116082 Rakprasit et al., Arch Gynecol Obstet 2023
- Prospective data from 3926 patients: urine hCG ≥500 IU/L associated with >35% risk of GTN; 70% of complete mole patients with urine hCG ≥10,000 IU/L developed GTN. Patients with partial mole and urine hCG <50 IU/L did not develop GTN. PMID 21684585 Alazzam et al., Gynecol Oncol 2011
- USA hCG Reference Service experience: hyperglycosylated hCG is the invasion stimulus in malignant GTD; quiescent GTD shows no/very low hyperglycosylated hCG; minimally invasive disease is chemorefractory; waiting until hCG >3000 IU/L before chemotherapy was successful in 10/10 minimally invasive cases. PMID 19822356 Cole & Muller, Gynecol Oncol 2010
- Proportion hyperglycosylated hCG marks cases intent on developing persistent hydatidiform mole (68% detection, 17% false detection), persistent hydatidiform mole (100% detection, 5.1% false detection), and identifies quiescent GTD cases that become persistent disease (100% detection, 0% false positive). PMID 25275660 Cole, Int J Gynecol Cancer 2014
- Prenatal screening for Down syndrome Human observational
- Multicenter study of 21,641 samples: hyperglycosylated-hCG detected 52% of first-trimester and 65% of second-trimester Down syndrome pregnancies above the 95th centile. At 3% false-positive rate, combined screening (age, NT, PAPP-A, h-hCG) detected 78% of cases. h-hCG was as strong a marker as free-beta between 10 and PMID 17590886 Palomaki et al., Prenat Diagn 2007
- Tumor marker for nontrophoblastic cancers (hCGβ free subunit) Human observational
- Review: serum free hCGβ or its urinary degradation product β-core fragment produced by 68% of ovarian, 51% of endometrial, and 46% of cervical malignancies; enhances growth and invasion; serves as a tumor marker. PMID 19007977 Muller & Cole, Gynecol Oncol 2009
- Review: ectopic hCGβ expression described in many cancer subtypes including breast cancer; hCGβ proposed as biomarker of malignancy and as potential vaccine target (tumor vaccine protected against mammary tumors in mice). PMID 20654692 Iles et al., Mol Cell Endocrinol 2010
- Monitoring hCG decline after medical abortion Human observational
- Prospective study of 59 women undergoing medical abortion (200 mg mifepristone + 800 mcg buccal misoprostol, ≤63 days gestation): mean hCG decline was 70.0% by Day 3 and 91.4% by Day 5; 97.1% by Days 7–9; decline rate unaffected by initial hCG or gestational duration. PMID 27621046 Pocius et al., Contraception 2017
- Endometrial receptivity improvement via hCG-loaded exosomal delivery (in vitro / experimental) In vitro only
- In vitro study: hCG loaded into uterine fluid exosomes (sonication: 710.05±73.74 IU/mg loading capacity; freeze-thaw: 245.06±95.66 IU/mg) upregulated LIF and Trophinin and downregulated Muc-16 and IGFBP1 in endometrial cells more effectively than hCG alone. PMID 33737084 Hajipour et al., Life Sci 2021
- Role of bcf-hCG in embryo implantation (animal/in vitro) Mixed
- In vitro and mouse ex vivo study: bcf-hCG was highly abundant in placenta and endometrial glands during early pregnancy; induced proliferation of stromal epithelial cell line; intrauterine injection in mice induced HOXA10 expression; bcf-hCG-treated embryos showed higher implantation rate than controls. PMID 40869294 Ryu et al., Int J Mol Sci 2025
Safety signals
- Ovarian hyperstimulation syndrome (OHSS): a recognized risk with hCG trigger in IVF, motivating development of reduced-dose dual trigger protocols to maintain efficacy while lowering OHSS rates. PMID 41239008
- Dose-dependent follicular cyst development in gilts receiving supplemental hCG after standard eCG/hCG treatment; frequency and number of cysts increased significantly with higher additional hCG doses (100 IU and 200 IU). PMID 26130853
- Commercial urinary-derived hCG preparations may contain contaminating growth factors (EGF, TGF-β1) that can cause off-target biological effects (e.g., ERK1/2 activation, TGFβR activation) attributable to contaminants rather than hCG itself. PMID 26495869
- False-positive hCG results from rheumatoid factor interference can lead to unnecessary diagnostic investigations or harmful therapy; PEG precipitation or alternative platforms are needed to identify the artefact. PMID 39661999
- Passive transfer of hCG from plasma products (e.g., plasma from an unknowingly pregnant donor) can cause spurious hCG elevation in plasma recipients, leading to misdiagnosis. PMID 29588177
- Pituitary hCG secretion can be elevated in post-orchiectomy males with high LH/FSH, mimicking occult tumor marker elevation; a GnRH antagonist test may be needed to distinguish pituitary vs. tumor source. PMID 31010310
- Low hyperglycosylated hCG at the time of implantation is associated with pregnancy failure (spontaneous abortion and biochemical pregnancy), though causality has not been established. PMID 22386126
- Many qualitative point-of-care urine hCG devices are susceptible to false-negative results at low hCG concentrations (<300 IU/L), with sensitivity insufficient to detect very early pregnancy (mean gestational age ~4 weeks for false negatives). PMID 23159297
- Erroneous reporting of hCG assay results is common: 9.3% of labs reported intact hCG results as total β-hCG, and 13.1% reported total β-hCG as intact hCG, posing clinical risks in pregnancy and oncology management. PMID 18375490
Contraindications
- The reviewed literature does not explicitly list contraindications to therapeutic hCG administration. The absence of contraindication data in these abstracts should not be interpreted as safety — manual verification with prescribing information is required. PMID 41239008
Protocol
500 iu subcutaneous injection, every other day (eod). Cycle: 3-4 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified (standard IVF trigger administration) | hCG-only: 5,000–10,000 IU hCG or 250–500 mcg Ovidrel; Dual trigger: 1,500 IU or 2,000 IU hCG + 2 mg GnRH agonist | Single administration (ovulation trigger) | human | Research PMID 41239008 |
| Intrauterine (via embryo transfer catheter) | Variable doses: <500 IU or ≥500 IU hCG (intrauterine/intracavity) | Single administration around time of embryo transfer | human | Research PMID 30341915 |
| Not specified (standard veterinary administration) | 500, 1000, or 2000 IU hCG (Exp.1); 1000 IU hCG (Exp.2) | Single administration two days after ovulation (Exp.1); single administration on Day 14 of protocol (Exp.2) | animal | Research PMID 40273828 |
| Not specified | 200 IU hCG (standard protocol) + additional 100 IU or 200 IU hCG at 24 h | Single additional dose at 24 h after standard eCG/hCG treatment | animal | Research PMID 26130853 |
| In vitro cell culture delivery | hCG loaded into exosomes: 710.05 ± 73.74 IU/mg (sonication) or 245.06 ± 95.66 IU/mg (freeze-thaw cycle) | In vitro / ex vivo experiment | in_vitro | Research PMID 33737084 |
| Serum measurement | Chemotherapy initiation recommended when hCG exceeds 3000 IU/L (serum monitoring threshold, not a therapeutic dose of hCG) | Monitoring threshold during GTD management | human | Research PMID 19822356 |
| subcutaneous injection | 500 IU | every other day (EOD) · 3-4 weeks | male TRT/anabolic steroid users during post-cycle therapy (PCT) | [Community] |
| subcutaneous injection | 250 IU | twice per week (e.g., Monday/Thursday) · ongoing, concurrent with TRT | men on testosterone replacement therapy (TRT) seeking to maintain testicular size and function | [Community] |
| subcutaneous injection | 500 IU | twice per week (e.g., Monday/Thursday) · ongoing, concurrent with TRT | men on TRT with more pronounced testicular atrophy or seeking stronger testicular stimulation | [Community] |
| subcutaneous injection | 1000 IU | every other day (EOD) · 10 days | male PCT users following heavy or prolonged anabolic steroid cycles | [Community] |
| intramuscular or subcutaneous injection | 1500 IU | three times per week · 3 weeks | men with secondary hypogonadism or low LH seeking fertility restoration under clinician supervision | [Community] |
| intramuscular injection | 2000 IU | every other day · 25 days | post-cycle male athletes recovering from long suppressive cycles | [Community] |
| subcutaneous injection | 125 IU | every other day (EOD) · ongoing, concurrent with TRT | TRT users seeking minimal but consistent testicular stimulation with reduced side effects | [Community] |
| intramuscular injection | 5000 IU | single dose or once per week for 1-2 weeks · 1-2 weeks | men with documented secondary hypogonadism under physician care; occasionally discussed by biohackers for 'kickstart' protocols | [Community] |
All studies (33)
- PMID 16877746 Human RCT
Ovulation induction and triggering in assisted reproduction (IVF/ICSI) - PMID 30341915 Human RCT
Intrauterine (intracavity) hCG administration to improve embryo implantation in subfertile women und - PMID 41239008 Human RCT
Ovulation induction and triggering in assisted reproduction (IVF/ICSI) - PMID 17590886 Human observational
Prenatal screening for Down syndrome - PMID 19007977 Human observational
Tumor marker for nontrophoblastic cancers (hCGβ free subunit) - PMID 19817556 Human observational
Pregnancy detection and monitoring (serum and urine hCG measurement) - PMID 19822356 Human observational
Diagnosis and monitoring of gestational trophoblastic disease (GTD) and gestational trophoblastic ne - PMID 20207583 Human observational
Monitoring and prediction of pregnancy outcome after IVF embryo transfer (serum β-hCG cutoff values) - PMID 20654692 Human observational
Tumor marker for nontrophoblastic cancers (hCGβ free subunit) - PMID 21684585 Human observational
Diagnosis and monitoring of gestational trophoblastic disease (GTD) and gestational trophoblastic ne - PMID 25246381 Human observational
Pregnancy detection and monitoring (serum and urine hCG measurement) - PMID 25275660 Human observational
Diagnosis and monitoring of gestational trophoblastic disease (GTD) and gestational trophoblastic ne - PMID 27621046 Human observational
Monitoring hCG decline after medical abortion - PMID 35733148 Human observational
Monitoring and prediction of pregnancy outcome after IVF embryo transfer (serum β-hCG cutoff values) - PMID 36116082 Human observational
Diagnosis and monitoring of gestational trophoblastic disease (GTD) and gestational trophoblastic ne - PMID 36279733 Human observational
Monitoring and prediction of pregnancy outcome after IVF embryo transfer (serum β-hCG cutoff values) - PMID 20653339 Mixed
Prevention of recurrent miscarriage (hCG supplementation) - PMID 40869294 Mixed
Role of bcf-hCG in embryo implantation (animal/in vitro) - PMID 18375490
Erroneous reporting of hCG assay results is common: 9.3% of labs reported intact hCG results as total β-hCG, and 13.1% reported total β-hCG as intact hCG, posin - PMID 22386126
Low hyperglycosylated hCG at the time of implantation is associated with pregnancy failure (spontaneous abortion and biochemical pregnancy), though causality ha - PMID 22455390
- PMID 23159297
Many qualitative point-of-care urine hCG devices are susceptible to false-negative results at low hCG concentrations (<300 IU/L), with sensitivity insufficient - PMID 25707740
- PMID 26130853 Animal studies only
Corpus luteum support and pregnancy rate improvement in bovine embryo transfer (animal model) - PMID 26495869
Commercial urinary-derived hCG preparations may contain contaminating growth factors (EGF, TGF-β1) that can cause off-target biological effects (e.g., ERK1/2 ac - PMID 29509368
- PMID 29588177
Passive transfer of hCG from plasma products (e.g., plasma from an unknowingly pregnant donor) can cause spurious hCG elevation in plasma recipients, leading to - PMID 30287399
- PMID 31010310
Pituitary hCG secretion can be elevated in post-orchiectomy males with high LH/FSH, mimicking occult tumor marker elevation; a GnRH antagonist test may be neede - PMID 32231662
- PMID 33737084 In vitro only
Endometrial receptivity improvement via hCG-loaded exosomal delivery (in vitro / experimental) - PMID 39661999
False-positive hCG results from rheumatoid factor interference can lead to unnecessary diagnostic investigations or harmful therapy; PEG precipitation or altern - PMID 40273828 Animal studies only
Corpus luteum support and pregnancy rate improvement in bovine embryo transfer (animal model)